Kornimate/medical-research-clean huggingface dataset:
insulin iontophoresis mixed with oleic acid versus topical insulin in patients with chronic diabetic foot ulcer

Conditions: Diabetes Mellitus

Summary: this study will be conducted to investigate the effect of insulin iontophoresis mixed with oleic acid versus topical insulin in patients with chronic diabetic foot ulcer

despite insulin treatment and a meticulously controlled diet, approximately 15% of all patients with diabetes will, at some time, have non-healing wounds and this is the leading cause of lower extremity amputation. wound healing involves cell adhesion, migration, proliferation, differentiation, and apoptosis at cellular and molecular levels. abnormalities of distinct factors of wound healing contribute to defective wound healing in diabetes ulcers, including decreased growth factor production, angiogenic response, macrophage function, collagen accumulation, epidermal barrier. insulin has great effect on ulcers healing and tissue regeneration but there is a catch that insulin is a large polymer that have difficulty crossing skin barrier but with using penetration enhancers like oleic acid combined with iontophoresis helps insulin to get through skin especially that affect locally on wound not systematic. insulin help in restoring the function and structure of the vasculature and improving angiogenesis, reduces the local wound blood glucose concentration, thus reducing the damage resulting from the accumulation of high levels of glucose metabolic intermediates, insulin is the inhibitor of three major proinflammatory transcription factors: nuclear factor-κb, activator protein-1 and early growth response-1 (egr-1). insulin relieves the inflammatory response and prevents an excessive inflammatory reaction. furthermore, insulin inhibits the degradation of immune cell proteins, thus enhancing immune activity. 45 patients with diabetic feet will be assigned randomly into 3 equal group; group a will receive insulin iontophoresis for 13 sessions, group b will receive topical insulin and group c will receive saline dressing for 13 weeks

Eligibility criteria:
inclusion criteria: * all patients had chronic wound at foot * the patients ages were ranged from 40 to 70 years * the subjects were chosen from both sexes * all patients were diabetic patients exclusion criteria: * uncontrolled wound bleeding * severe malnutrition * severeinfection * immunodeficiency * age\>70 years * renal failure * liver dysfunction * ischaemic limbs
risk prediction model for iodinated contrast medium extravasation

Conditions: Extravasation of Contrast Media

Summary: this study aims to develop a risk prediction model for iodine contrast agent extravasation from peripheral veins and to implement this model clinically to establish a risk control management system for iodine contrast agent extravasation.a case-control study design was employed to collect data for model development. the case group comprised patients who experienced iodine contrast agent extravasation during enhanced ct examinations, while the control group included patients who underwent similar examinations without extravasation.

in this study, a retrospective case-control design was utilized to collect data from patients who underwent enhanced ct examinations at our medical center. in line with the nursing management protocols of our center, all cases of iodine contrast extravasation require treatment and follow-up, necessitating the creation of an electronic record for each affected patient. during the establishment of these records, researchers obtained consent from the affected patients to include them in the study. upon receiving approval, relevant data from the records were extracted for research purposes. for the non-extravasation group, researchers approached eligible patients or their guardians after the examination, explained the study's objectives, and collected pertinent data through electronic medical record system after obtaining informed consent. the collected data encompass general demographic information (including age, gender, height, and weight), medical history (including conditions such as malignant tumors, chemotherapy treatments, hypertension, and diabetes), and examination parameters (including specific examination items, types of contrast agents, injection dosages, and flow rates). additionally, the dataset includes venous access details (such as vascular conditions, peripheral venous catheter insertion sites, and catheter models) and environmental factors (such as maximum and minimum temperatures and temperature variations).

Eligibility criteria:
inclusion criteria: 1. volunteer to participate in this study. 2. without contraindications such as iodine contrast allergy or hyperthyroidism. - exclusion criteria: 1. there are communication barriers between researchers and patients. 2. due to critical condition or unstable vital signs, patients should be transferred to relevant clinical departments for treatment or observation immediately after examination.

Keywords: extravasation of contrast media predictive models machine risk management
comparing naat testing to standard methods for the diagnosis of vaginitis

Conditions: Bacterial Vaginosis; Vulvovaginal Candidiasis; Trichomoniasis

Summary: vaginitis is the most common condition encountered in the gynecologist's office and is most commonly caused by bacerial vaginosis (bv), vulvovaginal candidiasis (vvc) and trichomonas vaginalis (tv). establishing the correct etiology of symptomatic vaginitis can be challenging, and the evaluation of vaginitis by physicians is often substandard. the investigators will determine whether naat testing will improve the diagnosis of vaginal infections including bacterial vaginosis (bv), vulvovaginal candidiasis (vvc) and trichomonas vaginalis (tv).

several commercial nucleic acid amplification tests (naat) are available to identify causative organisms. one of these commercial tests has undergone validation published in a scientific journal, only in an std clinic population. the primary outcome of this study is to compare naat diagnostic methods to traditional gold-standard tests for bv, vvc and tv in symptomatic and asymptomatic women in the general gynecology office as well as in a vulvovaginitis referral office. addressing incorrect evaluation and diagnosis will lead to correct treatment for women suffering from vaginitis.

Eligibility criteria:
inclusion criteria: 1. female participants aged 18 and older 2. based on symptoms: * symptomatic patients: with symptoms of vaginitis that include abnormal discharge, malodor, itching, irritation and / or discomfort * asymptomatic controls: no vulvovaginal symptoms 3. willing to provide written informed consent for participation in this study exclusion criteria: 1. use of oral antibiotics in the past 14 days 2. use of vaginal products or lubricant, vaginal intercourse, or douching in the last 24 hour

Keywords: bacterial vaginosis vulvovaginal candidiasis trichomoniasis
complications and long-term satisfaction in autologous vs. implant-based breast reconstruction

Conditions: Complications, Postoperative/Perioperative; Quality of Life; Satisfaction, Patient

Summary: current literature on complications and health-related quality of life in autologous and alloplastic breast reconstruction is inconclusive. despite the great demand for more in-depth, long-term studies of both techniques, current evidence is low or moderate and there are only few studies focusing on both health-related quality of life and complication rates in the same patient collective. this study aims at investigating the complex relationship between the occurrence of complications and patient-reported long-time satisfaction in autologous and alloplastic breast reconstruction.

the study is conducted at the medical university of graz and has been approved by the responsible ethics' committee (ek: 32-235 ex 19/20). the study includes female breast cancer patients who underwent elective breast reconstruction at one of the participating departments between april 2020 and april 2023. written informed consent was obtained from all individual study participants enrolled. exclusion criteria is defined as: * missing or insufficient information * combination of reconstruction techniques on the same breast * reconstruction procedures with insufficient number of cases * inability to fully understand study procedures and to provide informed consent data were first collected retrospectively from the clinical data management programs using surgical reports, outpatient charts, and physicians' letters. personal data such as patient age, concomitant diseases, nicotine abuse, anticoagulation status, previous oncological therapy and surgery, etc. were acquired. furthermore, surgery-related data (site and type of reconstruction, size and location of implant/tissue expander, intraoperative complications) and data on the postoperative course (early and late complications, revision surgeries, number of total surgeries required, etc.) were acquired. the five-level modified clavien-dindo classification is used to objectively classify postoperative complications, to allow further comparisons between treatment options, different time periods and correlations to health-related quality of life. postoperative changes in health-related quality of life are measured using the breast-q questionnaire, an effective and reliable patient-reported outcome measure in breast reconstruction.

Eligibility criteria:
inclusion criteria: * female breast cancer patient undergoing autologous or alloplastic breast reconstruction willing to participate in this study * age between 18 and 80 years (upper limit due to indication for breast reconstruction) * written informed consent exclusion criteria: * missing or insufficient information * combination of reconstruction techniques on the same breast * reconstruction procedures with insufficient number of cases * inability to fully understand study procedures and to provide informed consent
immunotherapy in lung cancer: treatment after io cessation.

Conditions: Carcinoma, Non-Small-Cell Lung; Immunotherapy

Summary: immunotherapy is now a standard of care for first-line and eventually salvage therapy in patients with stage iv nsclc and as adjuvant after rt-ct for stage iii nsclc. the aim of the study is determining the therapeutic landscape and the reason for immunotherapy cessation.

patients with stage iv or unresectable not irradiable stage iii nsclc will be registered at the time receiving immunotherapy alone or in combination with chemotherapy. when io is stopped, reason for cessation and further treatment will be recorded. secondary endpoints are survival after io cessation, activity of first salvage therapy, disease-free survival after io cessation in patients receiving no further treatment. patients will be centrally registered at the elcwp headquarter (institut jules bordet, brussels, belgium).

Eligibility criteria:
inclusion criteria: * histological diagnosis of non-small cell lung cancer (nsclc) * stage iva/ivb and unresectable and non irradiable stage iii nsclc naïve of immunotherapy. * patients who receive immunotherapy (any type) monotherapy, combined immunotherapy or in combination with chemotherapy for first or second-line treatment. * availability for participating in the detailed follow-up of the protocol. * signed informed consent. exclusion criteria: * patients receiving adjuvant immunotherapy for stage i-iii nsclc are not eligible * tumours for which tnm stage at time of study inclusion cannot be assessed. * history of prior malignant tumour, except non-melanoma skin cancer or in situ carcinoma of the cervix or of the bladder or cured malignant tumor (more than 5-year disease free interval). * any type of immunotherapy for previous cancer
effects of vitamin d on bone, muscle, and adipose tissue in obese subjects

Conditions: Musculoskeletal Diseases; Inflammation; Sarcopenic Obesity

Summary: obesity has emerged as a risk factor in the onset of bone, muscle and adipose tissue impairments that are further aggravated by vitamin d deficiency. a link of an active bone-muscle-adipose axis is represented by wnt pathway. this study will test the hypothesis that vitamin d improves bone, muscle, and adipose tissue health through a positive modulation of wnt pathway. it will be carried out a double-blind, placebo-controlled study of cholecalciferol supplementation in vitamin d-deficient obese adults. specific aims will be: 1) to test the direct effect of vitamin d on wnt signaling in bone, muscle, and adipose tissue; 2) to evaluate muscle mass and strength; 3) to assess changes in vitamin d status across different administration strategy (weekly, fortnightly, monthly). this study will provide not only insight of new mechanisms involved in the pathophysiology of obesity-related musculoskeletal impairments but also evidence for new treatment recommendations for vitamin d deficiency in obesity.


Eligibility criteria:
inclusion criteria: * ambulatory willing and able to provide informed consent; * post-menopausal women (55-75 y.o.) and age-matched men; * bmi 30 \>= kg/m2; * serum 25ohd \< 20 ng/ml * hip replacement surgery due to osteoarthritis according to orthopedic clinical decision exclusion criteria: * egfr \<40 ml/min/1.72 m2 by epi formula (21); * hypercalcemia (\>10.5 mg/dl); * osteoporosis (hip or vertebral t-score \>-2.5); * conditions affecting bone * vitamin d and/or calcium metabolism (chronic liver disease, renal failure, malabsorption, hypercortisolism); * medications altering bone metabolism (e.g. denosumab, bisphosphonates, teriparatide, glucocorticoids, aromatase inhibitors, estrogen); * enrollment in an interventional clinical trial in the previous 3 months.
efficacy and safety of ledipasvir/sofosbuvir fixed dose combination in the treatment of hepatitis c virus (hcv) infection in pediatric participants undergoing cancer chemotherapy

Conditions: Hepatitis C Virus Infection

Summary: the primary objectives of this study are to evaluate the efficacy, safety, and tolerability of ledipasvir/sofosbuvir (ldv/sof) in treating hepatitis c virus (hcv) infection in pediatric participants who are undergoing cancer chemotherapy.


Eligibility criteria:
key inclusion criteria: * aged 12 to \<18 years * parent or legal guardian must provide written informed consent * treatment naïve or experienced children with genotype 1 or 4 hcv infection, and are on a maintenance cancer chemotherapy regimen * receiving a protocol-approved maintenance chemotherapy regimen for a hematological malignancy * chronic hcv infection (≥ 6 months) documented by medical history or liver biopsy * screening laboratory values within defined thresholds * no history of solid organ or bone marrow transplantation * no history of clinical hepatic decompensation (eg, ascites, jaundice, encephalopathy, variceal hemorrhage) note: other protocol defined inclusion/ exclusion criteria may apply.

Keywords: hcv genotype 1 or 4 (gt-1 or gt-4) direct acting antiviral combination therapy hepatitis c, chronic liver diseases virus diseases
evaluation of a new eus guided biopsy needle (sharkcore) comparing to standard eus needle (procore)

Conditions: Mesenchymal Tumor; Autoimmune Pancreatitis; Lymphoma; Solid Tumors

Summary: diagnosis of lesions of pancreas, the upper gastrointestinal tract, as well as adjacent structures, such as lymph nodes, is still showing advancements especially with the increased use of endoscopic ultrasound. endoscopic ultrasound-guided fine needle aspiration and fine needle biopsy (eus-fna/fnb) have become mainstay diagnostic techniques for these lesions. the purpose of the study is to compare between the currently used, procore needles and the new biopsy needle, sharkcore, for the histological diagnosis and evaluation of lesions.

endoscopic ultrasound-guided fine needle aspiration and fine needle biopsy (eus-fna/fnb) have become mainstay diagnostic techniques for the diagnosis and evaluation of lesions of the pancreas, the upper gastrointestinal tract, as well as adjacent structures, including lymph nodes. cytology specimens provided from fna cannot fully characterize certain neoplasms such as lymphomas or mesenchymal tumors. core biopsy specimens for histological examinations are needed to provide accurate diagnoses. procore needles (procore, wilson-cook medical inc. winston-salem, nc) were designed to obtain histological and cytological samples. studies comparing procore needles with standard fna needles showed no significant difference in diagnostic accuracy, histological core tissue procurement or mean number of passes. to overcome the above mentioned limitations (mainly suboptimal core tissue procurement rates), a new novel sharkcore needle (beacon endoscopic, newton, ma, usa) has been designed and approved for clinical human use by the fda. the objective of the study is to compare the new eus guided histology biopsy needle sharkcore to the currently used eus histology needle, procore, for the histological diagnosis and evaluation of lesions.

Eligibility criteria:
inclusion criteria: patients ≥ 18 years of age referred for eus lesions requiring histologic diagnosis: * mesenchymal tumors * autoimmune pancreatitis * granulomatous disease * indeterminate hepatitis * confirmatory immunochemistry to establish a diagnosis (i.e. pancreatic neuroendocrine tumor) * lymphoma * solid tumors * previously non-diagnostic fna exclusion criteria: * uncorrectable coagulopathy (inr \> 1.5) * uncorrectable thrombocytopenia (platelet \< 50,000) * uncooperative patients * pregnant women (women of childbearing age will undergo urine pregnancy testing, which is routine for all endoscopic procedures) * refusal to consent form * cystic lesions * inaccessible lesions to eus (proximal to sigmoid colon or distal to second duodenum)

Keywords: sharkcore procore
measurement of sweat sodium concentration in patients with chronic kidney disease

Conditions: Chronic Kidney Diseases

Summary: it has been shown that excretion of sodium and water through the skin in the form of sweat represents a regulatory mechanism of electrolyte- and fluid balance. since patients with chronic kidney disease (ckd) exhibit increased skin sodium content, we investigated the feasibility of sweat testing as a novel experimental tool to a more complete assessment of fluid- and sodium homeostasis. in this cross-sectional feasibility study, we applied pilocarpine iontophoresis to induce sweat testing in 58 patients across various stages of ckd including patients after kidney transplantation as well as a healthy control cohort (n=6) to investigate possible effects of ckd and transplantation status on sweat rate and sodium concentration. due to non-linear relationships, we modeled our data using polynomial regression. decline of kidney function showed a significant association with lower sweat rates: adj r²= 0.2278, f(2, 61) = 10.29, p = 0.000141. sweat sodium concentrations were increased in moderate ckd, however this effect was lost in end stage renal disease: adj r² = 0.3701, f(4, 59) = 10.26, p = 2.261e-06. we observed higher sweat weight in males compared to females. diagnostic sweat analysis represents an innovative and promising noninvasive option for more thorough investigation of sodium- and fluid homeostasis in ckd patients. lower sweat rates and higher sweat sodium concentrations represent a unique feature of ckd patients with potential therapeutic implications.


Eligibility criteria:
inclusion criteria: completed 18th year of life and the ability and willingness to provide informed consent exclusion criteria: general exclusion criteria were signs of acute infection, clinical signs of kidney graft rejection or pregnancy. exclusion criteria for the healthy controls were pregnancy or the presence of chronic metabolic, renal, cardiovascular, or rheumatologic conditions, hypertension, chronic or recent intake (8 weeks prior to testing) of psychiatric or antihypertensive medication.
evaluate efficacy, and safety of topical therapy and etanercept in subjects with moderate to severe plaque psoriasis

Conditions: Psoriasis

Summary: the primary hypothesis of this trial is that the addition of short courses of clobetasol propionate foam to etanercept monotherapy in subjects with moderate to severe plaque psoriasis will yield greater efficacy compared with etanercept monotherapy, as measured by pasi 75 at week 12.


Eligibility criteria:
inclusion criteria: * subject has had stable moderate to severe plaque psoriasis for at least 6 months * subject has involved bsa ≥ 10% and pasi ≥ 10 at screening and at baseline. * subject is a candidate for systemic therapy or phototherapy in the opinion of the investigator exclusion criteria: * subject has active guttate, erythrodermic, or pustular psoriasis at the time of the screening visit. * subject has evidence of skin conditions at the time of the screening visit (eg, eczema) that would interfere with evaluations of the effect of etanercept and/orclobetasol propionate foam on psoriasis. * subject diagnosed with medication-induced or medication exacerbated psoriasis * subject has any active common toxicity criteria (ctc) grade 2 or higher infection * subject has a significant concurrent medical condition or laboratory abnormalities as defined in the study protocol. * subject has used any of the following therapies within 14 days of the first dose: uvb therapy or topical psoriasis therapies other than class i or ii topical steroids. * subject has used any of the following therapies within 28 days of the first dose: class i or ii topical steriods, uva therapy (with or without psoralen), or systemic psoriasis therapies * subject has used one or more biologic therapies (other than interleukin (il)12/il23 inhibitors) within 3 months of the first dose * subject has used an il-12/il-23 inhibitor within 6 months of the first dose of etanercept * subject has ever used efalizumab (raptiva®).

Keywords: psoriasis topical etanercept clobetasol propionate
covid-19 infection control using h2o2 mouth wash and nasal spray

Conditions: COVID-19

Summary: hydrogen peroxide is produced physiologically by oral bacteria and plays a significant role in the balance of oral microecology since it is an important antimicrobial agent. in the epithelial cells, the enzyme superoxide dismutase catalyzes a reaction leading from hydrogen peroxide to the ion superoxide. the induced oxidative stress stimulates a local innate response via activation of the toll-like receptors and the nf-κb. those kinds of reactions are also activated by viral infections. virus-induced oxidative stress plays an important role in the regulation of the host immune system and the specific oxidant-sensitive pathway is one of the effective strategies against viral infections. therefore, nose/mouth/throat washing with hydrogen peroxide may enhance those local innate responses to viral infections. the investigators hypothesised that a treatment with a mouth wash and a nasal spray containing a diluted solution of hydrogen peroxide may accelerate the negativisation rate of a positive pcr swab test for sars-cov-2 (covid-19).


Eligibility criteria:
inclusion criteria: - recent positive sars-cov-2 pcer swab test exclusion criteria: - severe covid19 disease
support for increased physical activity (stöd till aktivare motion)

Conditions: Overweight

Summary: the purpose of this study is to improve and analyze the level of physical activity in immigrant women from the middle east and latin america living in sweden. the investigators will also investigate if glucose, insulin, and lipid metabolism; stress-related hormone production; and subclinical inflammatory activity are affected by the intervention. the follow-up period is 2 years.


Eligibility criteria:
inclusion criteria: * female gender * age 25 through 64 years * physical inactivity * bmi \> 25 * immigrant to sweden from either the middle east or latin america exclusion criteria: * diabetes mellitus type i * ischemic heart disease * disability that interferes with the ability to participate in lifestyle-related physical activity

Keywords: overweight physical inactivity physical fitness lifestyle change